{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2025,10,31]],"date-time":"2025-10-31T13:53:00Z","timestamp":1761918780718},"reference-count":32,"publisher":"Japanese Society of Internal Medicine","issue":"11","content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["Intern. Med."],"published-print":{"date-parts":[[2005]]},"DOI":"10.2169\/internalmedicine.44.1163","type":"journal-article","created":{"date-parts":[[2005,12,16]],"date-time":"2005-12-16T05:56:17Z","timestamp":1134712577000},"page":"1163-1168","source":"Crossref","is-referenced-by-count":11,"title":["Pathological Complete Response in Advanced Gastrointestinal Stromal Tumor after Imatinib Therapy"],"prefix":"10.2169","volume":"44","author":[{"given":"Bohuslav","family":"MELICHAR","sequence":"first","affiliation":[{"name":"Department of Oncology & Radiotherapy Charles University Medical School & Teaching Hospital, Hradec, Kr\u00e1lov\u00e9"},{"name":"Department of Medicine Charles University Medical School & Teaching Hospital, Hradec, Kr\u00e1lov\u00e9"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Zbynek","family":"VOBORIL","sequence":"additional","affiliation":[{"name":"Department of Surgery Charles University Medical School & Teaching Hospital, Hradec, Kr\u00e1lov\u00e9"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Jan","family":"NOZICKA","sequence":"additional","affiliation":[{"name":"Department of Pathology Charles University Medical School & Teaching Hospital, Hradec, Kr\u00e1lov\u00e9"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Ales","family":"RYSKA","sequence":"additional","affiliation":[{"name":"Department of Pathology Charles University Medical School & Teaching Hospital, Hradec, Kr\u00e1lov\u00e9"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Hana","family":"URMINSK\u00c1","sequence":"additional","affiliation":[{"name":"Department of Radiology Charles University Medical School & Teaching Hospital, Hradec, Kr\u00e1lov\u00e9"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Tom\u00e1s","family":"VANECEK","sequence":"additional","affiliation":[{"name":"Department of Pathology, Charles University Medical School & Teaching Hospital, Plzen, Czech Republic"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Michal","family":"MICHAL","sequence":"additional","affiliation":[{"name":"Department of Pathology, Charles University Medical School & Teaching Hospital, Plzen, Czech Republic"}],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"962","reference":[{"key":"1","doi-asserted-by":"crossref","unstructured":"1) Nilsson B, Bumming P, Meis-Kindblom JM, et al. Gastrointestinal stromal tumors: the incidence, prevalence, clinical course, and prognostication in the preimatinib mesylate era. A population-based study in western Sweden. Cancer <b>103<\/b>: 821-829, 2005.","DOI":"10.1002\/cncr.20862"},{"key":"2","doi-asserted-by":"crossref","unstructured":"2) Miettinen M, Sobin LH, Lasota J. Gastrointestinal stromal tumors of the stomach. A clinicopathologic immunohistochemical, and molecular genetic study of 1765 cases with long-term follow-up. Am J Surg Pathol <b>29<\/b>: 52-68, 2005.","DOI":"10.1097\/01.pas.0000146010.92933.de"},{"key":"3","doi-asserted-by":"crossref","unstructured":"3) Crosby JA, Catton CN, Davis A, et al. Malignant gastrointestinal stromal tumors of the small intestine: A review of 50 cases from a prospective database. Ann Surg Oncol <b>8<\/b>: 50-59, 2001.","DOI":"10.1007\/s10434-001-0050-4"},{"key":"4","doi-asserted-by":"crossref","unstructured":"4) Ng EH, Pollock RE, Romsdahl MM. Prognostic implications of patterns of failure for gastrointestinal leiomyosarcomas. Cancer <b>69<\/b>: 1334-1341, 1992.","DOI":"10.1002\/1097-0142(19920315)69:6<1334::AID-CNCR2820690606>3.0.CO;2-S"},{"key":"5","doi-asserted-by":"crossref","unstructured":"5) DeMatteo RP, Shah A, Fong Y, Jarnagin WR, Blumgart LH, Brennan MF. Results of hepatic resection for sarcoma metastatic to liver. Ann Surg <b>234<\/b>: 540-548, 2001.","DOI":"10.1097\/00000658-200110000-00013"},{"key":"6","doi-asserted-by":"publisher","DOI":"10.1097\/00000658-200001000-00008"},{"key":"7","doi-asserted-by":"publisher","DOI":"10.1007\/s004280000338"},{"key":"8","doi-asserted-by":"publisher","DOI":"10.1200\/JCO.2003.04.190"},{"key":"9","doi-asserted-by":"publisher","DOI":"10.1053\/hupa.2002.124122"},{"key":"10","doi-asserted-by":"crossref","unstructured":"10) Edmonson JH, Marks RS, Buckner JC, Mahoney MR. Contrast of response to dacarbazine, mitomycin, doxorubicin, and cisplatin (DMAP) plus GM-CSF between patients with advanced malignant gastrointestinal stromal tumors and patients with other advanced leiomyosarcomas. Cancer Invest <b>20<\/b>: 605-612, 2002.","DOI":"10.1081\/CNV-120002485"},{"key":"11","unstructured":"11) Melichar B, Voboril Z, Nozicka J, et al. Hepatic arterial infusion chemotherapy in sarcoma liver metastasis: A report of 6 cases. Tumori <b>91<\/b>: 19-23, 2005."},{"key":"12","doi-asserted-by":"publisher","DOI":"10.1038\/sj.onc.1204704"},{"key":"13","doi-asserted-by":"publisher","DOI":"10.1056\/NEJMoa020461"},{"key":"14","doi-asserted-by":"publisher","DOI":"10.1016\/S0140-6736(01)06535-7"},{"key":"15","doi-asserted-by":"crossref","unstructured":"15) Eisenberg BL, Judson I. Surgery and imatinib in the management of GIST: emerging approaches to adjuvant and neoadjuvant therapy. Ann Surg Oncol <b>11<\/b>: 465-475, 2004.","DOI":"10.1245\/ASO.2004.09.011"},{"key":"16","doi-asserted-by":"crossref","unstructured":"16) Wu PC, Langerman A, Ryan CW, Hart J, Swiger S, Posner MC. Surgical treatment of gastrointestinal stromal tumors in the imatinib (STI-571) era. Surgery <b>134<\/b>: 656-666, 2003.","DOI":"10.1016\/S0039-6060(03)00314-3"},{"key":"17","doi-asserted-by":"crossref","unstructured":"17) Bumming P, Andersson J, Meis-Kindblom JM, et al. Neoadjuvant, adjuvant and palliative treatment of gastrointestinal stromal tumors (GIST) with imatinib: a centre-based study of 17 patients. Br J Cancer <b>89<\/b>: 460-464, 2003.","DOI":"10.1038\/sj.bjc.6600965"},{"key":"18","doi-asserted-by":"publisher","DOI":"10.1016\/j.amjsurg.2003.08.023"},{"key":"19","doi-asserted-by":"crossref","unstructured":"19) Hes O, Vanecek T, Perez-Montiel DM, et al. Chromophobe renal cell carcinoma with microcystic and adenomatous arrangement and pigmentation&mdash;a diagnostic pitfall. Morphological, immunohistochemical, ultrastructural and molecular genetic report of 20 cases. Virchows Arch <b>446<\/b>: 383-393, 2005.","DOI":"10.1007\/s00428-004-1187-x"},{"key":"20","doi-asserted-by":"publisher","DOI":"10.1056\/NEJM200104053441404"},{"key":"21","unstructured":"21) Rutkowski P, Nyckowski P, Grzesiakowska U, et al. The clinical characteristics and the role of surgery and imatinib treatment in patients with liver metastases from c-kit positive gastrointestinal stromal tumors (GIST). Neoplasma <b>50<\/b>: 438-442, 2003."},{"key":"22","doi-asserted-by":"crossref","unstructured":"22) Yao KA, Talamonti MS, Langella RL, et al. Primary gastrointestinal sarcomas: Analysis of prognostic factors and results of surgical management. Surgery <b>128<\/b>: 604-612, 2000.","DOI":"10.1067\/msy.2000.108056"},{"key":"23","doi-asserted-by":"crossref","unstructured":"23) Chen H, Pruitt A, Nicol TL, Gorgulu S, Choti MA. Complete hepatic resection of metastases from leiomyosarcoma prolongs survival. J Gastrointest Surg <b>2<\/b>: 151-155, 1998.","DOI":"10.1016\/S1091-255X(98)80006-1"},{"key":"24","doi-asserted-by":"crossref","unstructured":"24) Lang H, Nussbaum KT, Kaudel P, Fruhauf N, Flemming P, Raab R. Hepatic metastases from leiomyosarcoma. A single-center experience with 34 resections during a 15-year period. Ann Surg <b>231<\/b>: 500-505, 2000.","DOI":"10.1097\/00000658-200004000-00007"},{"key":"25","doi-asserted-by":"crossref","unstructured":"25) Carson W, Karakousis C, Douglass H, Rao U, Palmer ML. Results of aggressive treatment of gastric sarcoma. Ann Surg Oncol <b>1<\/b>: 244-251, 1994.","DOI":"10.1007\/BF02303530"},{"key":"26","doi-asserted-by":"publisher","DOI":"10.2169\/internalmedicine.43.1151"},{"key":"27","unstructured":"27) Fiorentini G, Bernardesci P, De Simone M, et al. Efficacy of imatinib mesylate in patients with liver metastases from gastrointestinal stromal tumor failing intra-arterial hepatic chemotherapy with epirubicin. J Exp Clin Cancer Res <b>22<\/b> (Supplement): 13-16, 2003."},{"key":"28","doi-asserted-by":"crossref","unstructured":"28) Verweij J, van Oosterom A, Blay JY, et al. Imatinib mesylate (STI-541 Glivec, Gleevec) is an active agent for gastrointestinal stromal tumours, but does not yield responses in other soft-tissue sarcomas that are unselected for a molecular target: Results from an EORTC Soft Tissue and Bone Sarcoma Group phase II study. Eur J Cancer <b>39<\/b>: 2006-2011, 2003.","DOI":"10.1016\/S0959-8049(02)00836-5"},{"key":"29","doi-asserted-by":"crossref","unstructured":"29) Verweij J, Casali PG, Zalcberg J, et al. Progression-free survival in gastrointestinal stromal tumours with high-dose imatinib: randomised trial. Lancet <b>364<\/b>: 1127-1134, 2004.","DOI":"10.1016\/S0140-6736(04)17098-0"},{"key":"30","doi-asserted-by":"crossref","unstructured":"30) Reichardt P, Schneider U, Stroszczynski C, Pink D, Hohenberger P. Molecular response of gastrointestinal stromal tumour after treatment with tyrosine kinase inhibitor imatinib mesylate. J Clin Pathol <b>57<\/b>: 215-217, 2004.","DOI":"10.1136\/jcp.2004.11379"},{"key":"31","doi-asserted-by":"crossref","unstructured":"31) Chacon M, Roca E, Huertas E, Loria FS, Domenechini E. Case 3. Pathologic complete remission of metastatic gastrointestinal stromal tumor after imatinib mesylate. J Clin Oncol <b>23<\/b>: 1580-1582, 2005.","DOI":"10.1200\/JCO.2005.03.194"},{"key":"32","doi-asserted-by":"crossref","unstructured":"32) Chollet P, Amat S, Cure H, et al. Prognostic significance of a complete pathological response after induction chemotherapy in operable breast cancer. Br J Cancer <b>86<\/b>: 1041-1046, 2002.","DOI":"10.1038\/sj.bjc.6600210"}],"container-title":["Internal Medicine"],"original-title":[],"language":"en","link":[{"URL":"http:\/\/www.jstage.jst.go.jp\/article\/internalmedicine\/44\/11\/44_11_1163\/_pdf","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2021,5,19]],"date-time":"2021-05-19T17:23:07Z","timestamp":1621444987000},"score":1,"resource":{"primary":{"URL":"http:\/\/www.jstage.jst.go.jp\/article\/internalmedicine\/44\/11\/44_11_1163\/_article"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2005]]},"references-count":32,"journal-issue":{"issue":"11","published-print":{"date-parts":[[2005]]}},"URL":"https:\/\/doi.org\/10.2169\/internalmedicine.44.1163","relation":{},"ISSN":["0918-2918","1349-7235"],"issn-type":[{"value":"0918-2918","type":"print"},{"value":"1349-7235","type":"electronic"}],"subject":[],"published":{"date-parts":[[2005]]}}}